Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway.
The bone marrow microenvironment (BME) in acute myeloid leukemia (AML) consists of various cell types that support the growth of AML cells and protect them from chemotherapy. Mesenchymal stromal cells (MSCs) in the BME have been shown to contribute immensely to leukemogenesis and chemotherapy resist...
Main Authors: | Bin Yuan, Fouad El Dana, Stanley Ly, Yuanqing Yan, Vivian Ruvolo, Elizabeth J Shpall, Marina Konopleva, Michael Andreeff, Venkata Lokesh Battula |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0242809 |
Similar Items
-
The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment
by: Hong Zhang, et al.
Published: (2021-06-01) -
Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition
by: Amélie Foucault, et al.
Published: (2021-11-01) -
ALDH1-Mediated Autophagy Sensitizes Glioblastoma Cells to Ferroptosis
by: Yang Wu, et al.
Published: (2022-12-01) -
CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
by: Bo-Reum Kim, et al.
Published: (2020-06-01) -
ALDH2 variance in disease and populations
by: Che-Hong Chen, et al.
Published: (2022-06-01)